Clinical characteristics and prognosis analysis of patients with de novo ASXL1-mutated AML treated with the C-HUNAN-AML-15 protocol: A multicenter study by the South China Pediatric AML Collaborative Group.

Cancer Med · 2023 · PMC10315855 · PMID 37132266

Europe PMC DOI

hedged sentence

0.1590

closest p · 3.2× alpha

0.1590

boldest claim

The sentences

not significantly significantp = 0.159not close (p > 0.1)

The treatment‐related mortality with chemotherapy alone was not significantly significant than HSCT (7.5% [23/306] vs. 4.6% [11/240], p = 0.159).

also in 164 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.